Compare MTNB & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTNB | AIDX |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 3.0M |
| IPO Year | 2014 | 2025 |
| Metric | MTNB | AIDX |
|---|---|---|
| Price | $1.39 | $0.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 68.6K | ★ 142.9K |
| Earning Date | 08-13-2026 | 11-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.84 | 34.48 |
| EPS | ★ N/A | N/A |
| Revenue | $119,750.00 | ★ $2,045,133.00 |
| Revenue This Year | N/A | $44.20 |
| Revenue Next Year | N/A | $95.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 16.71 |
| 52 Week Low | $0.15 | $0.21 |
| 52 Week High | $3.16 | $18.96 |
| Indicator | MTNB | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 40.61 | 30.06 |
| Support Level | $0.56 | N/A |
| Resistance Level | $3.16 | $0.69 |
| Average True Range (ATR) | 0.25 | 0.02 |
| MACD | -0.14 | 0.00 |
| Stochastic Oscillator | 22.97 | 13.67 |
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.